Georgia Life Sciences Association Statement on the Release of the NSCEB Final Report and Action Plan

Emerging biotechnology is key for U.S. to remain dominant and secure future economic growth in a new era of global competition

Georgia Life Sciences (GLS) applauds the National Security Commission on Emerging Biotechnology (NSCEB) for its leadership and vision in publishing its final report and action plan to Congress. This comprehensive roadmap is a vital step toward securing and advancing U.S. leadership in biotechnology at a critical moment for our nation's competitiveness, security, and economic future.


We strongly support the Commission’s call for urgent federal action, including the proposed $15 billion in new investments over five years, to ensure the U.S. biotechnology sector remains the global leader in innovation and commercialization. These resources will help drive transformative advances across healthcare, manufacturing, national security, and more.


The timing of this report is especially critical as our nation’s life sciences research and innovation infrastructure, particularly at the National Institutes of Health (NIH) and the Food and Drug Administration (FDA), faces considerable uncertainty. Strong federal leadership and investment are essential to maintain the momentum of discovery, innovation, and public health progress.


The report’s 49 recommendations, organized across six strategic pillars, offer a bold and actionable framework:

  • Prioritize biotechnology at the national level
  • Mobilize the private sector to get U.S. products to scale
  • Maximize the benefits of biotechnology for defense
  • Out-innovate our strategic competitors
  • Build the biotechnology workforce of the future
  • Mobilize the collective strengths of our allies and partners


Georgia Life Sciences encourages members of the Georgia congressional delegation to endorse the Commission’s report and advocate for its swift and full implementation by the administration. Georgia's leadership in life sciences innovation positions our state to be a key contributor in realizing the report’s vision, and federal support is essential to maximizing this opportunity for both regional and national impact.


As Georgia continues to grow its vibrant life sciences ecosystem, we recognize the immense potential of a coordinated national strategy to accelerate innovation, empower our workforce, and foster public-private partnerships. We look forward to working with policymakers, industry partners, and research institutions to implement these recommendations and deliver biotechnology solutions that improve lives and strengthen our country. As the report states, without this type of transformational investment, our adversaries will work to leverage their biotech advancements to attack, destroy, starve, and harm the U.S.


The full text of the final report can be found here: https://biotech.senate.gov 

Announcement: https://www.biotech.senate.gov/press-releases/nsceb-publishes-final-report/

BIO's statement is here.

September 11, 2025
Members are invited to join G2G’s Monthly GBG Reporting Service Webinar on September 18, 2025 . The first portion ( 12:00–12:30 PM ET ) is free and open to all, offering a high-level overview of current federal funding trends. The second half ( 12:30–1:00 PM ET ) is a premium consultation available only to Georgia Life Sciences members, offering direct access to G2G’s expert team—who have helped secure over $550 million in non-dilutive government funding since 2007. Register here: https://www.g2gconsulting.com/event/non-dilutive-funding-g2gs-monthly-gbg-reporting-service-webinar-14-3/2025-09-18/ Key opportunities this month include DARPA’s Expedited Research Innovation System for CBRN threat defense technologies, BARDA’s I-CREATE diagnostic funding and VANGUARD biomanufacturing tools development (each offering up to $200,000), NIAID tuberculosis and influenza research units (up to $1.5–$2.5 million annually), DoD’s $4 million Advanced Medical Monitor development through MTEC, and multiple SBIR opportunities for sensors and field-deployable diagnostics (up to $209,575 for Phase I awards). The September GBG report highlights 13 immunology and infectious disease opportunities, 10 cognitive and brain health programs, and several biotechnology and biomanufacturing initiatives across federal agencies including the Army, ARPA-H, BARDA, and NSF. Georgia Life Sciences members can access the complete 29-page report with detailed deadlines and eligibility requirements [insert link or portal instructions here]. GLS members can access the full 29-page report with deadlines and submission details by logging into your member portal.
By Maria Thacker Goethe September 5, 2025
Protecting U.S. Leadership in Agricultural Biotechnology
By Maria Thacker Goethe August 29, 2025
Celebrating the Next Generation of Scientific Breakthroughs in Georgia
MORE POSTS